ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
General Electric has agreed to acquire Abbott Laboratories' in vitro and point-of-care diagnostics businesses for $8.13 billion in cash. The in vitro unit tests blood or urine samples to diagnose disease. GE says the new business will complement its existing in vivo diagnostic imaging systems, which use X-ray, magnetic resonance, and ultrasound to diagnose disease. The point-of-care unit manufactures diagnostic products for blood gas and blood chemistry analysis in doctors' offices and emergency rooms. The acquisition builds on GE's 2003 purchase of Amersham, a maker of imaging agents and drug discovery tools.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X